EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational ...
-YUTIQ™ approved by U.S. FDA; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and commercialize EyePoint’s three-year micro-insert product using the Durasert™ technology for posterior segment uveitis in …